Hazem Mustafa·Aug 22A Drug Asset Is Not a Molecule. It Is a Biological Hypothesis.Why pharmaceutical development should evolve with the biology it is continuously learning
Hazem Mustafa·Aug 21We Don’t Have a Data Problem in Biology. We Have a Representation Problem.Why the next frontier in biological understanding may depend less on measuring more, and more on changing what we believe disease actually…
Hazem Mustafa·Aug 19Biology-Led Venture CreationWhat If We Are Building Biotech Companies in the Wrong Order?
Hazem Mustafa·Jan 11Parkinson’s Doesn’t Have a Trial ProblemFor more than three decades, Parkinson’s disease research has been caught in a cycle of collective self-deception, one that has become so…
Hazem Mustafa·Dec 19, 2025Why Next-Gen ADCs Won’t Save the Modality Without Fundamental ChangeFor more than a decade, antibody–drug conjugates (ADCs) have been heralded as the long-awaited convergence of precision targeting and…
Hazem Mustafa·Dec 15, 2025Recursion and the Limits of AI-First Drug DiscoveryBy now, I may have a small bounty on my head for my article on Freenome.
Hazem Mustafa·Dec 6, 2025The Beginning of the End: A Decade, A Billion Dollars, and the Inescapable Logic of Biomarker…This is going to make a lot of people very uncomfortable.
Hazem Mustafa·Dec 4, 2025Beyond the Last Mile: What 10x Genomics Got Right And What Bioada Solved Years AgoRecently, I came across an insightful piece titled “10x Genomics on the Last-Mile Problem in Single-Cell Analysis”. Since I’ve always been…
Hazem Mustafa·Dec 2, 2025The GLP-1 Megatrend (4 of 4): The Payer Reckoning That Will Redefine the MarketFor all the scientific breakthroughs, commercial acceleration, and cultural momentum surrounding GLP-1–based therapies, the final and most…
Hazem Mustafa·Nov 27, 2025I Told You SoThe Ozempic–Alzheimer’s Failure Is Exactly What I Warned Would Happen